Jun 04,2019

Glooko Teams Up With Diabetes Nonprofit T1D

This morning, diabetes management platform Glooko announced that it is teaming up with Boston-based diabetes research nonprofit T1D Exchange, in an effort to integrate anonymized diabetes device data into T1D Exchanges Quality Improvement collaborative.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jun 28,2019

Livongo makes its IPO plans official

Months after the first rumors began to swirl, chronic disease management startup Livongo Health has officially filed for an IPO on the Nasdaq Global Select Market. The company has not yet determined a price range or the number of shares going on offer. Morgan Stanley & Co., Goldman Sachs & Co. and JP Morgan Securities will serve as the lead book runners.

View Analyst & Ambassador Comments
Go to original news
Jun 01,2019

Tidepool CEO Howard Look on Creating an Interoperable Ecosystem for Diabetes Data

The Palo Alto, Calif.-based nonprofit organization is working to allow people with diabetes to see the data from their insulin pump, continuous glucose monitor (CGM), and blood glucose meter all in one place.

View Analyst & Ambassador Comments
Go to original news
Jun 04,2019

DarioHealth Signs New Functional Medicine Clinic to Its Digital Diabetes Platform

Functional Medicine Center of Fort Collins will incorporate Dario's digital diabetes platform to its health and wellness improvement programs. Functional Medicine Center of Fort Collins was founded by Dr. Galyardt, a Functional Medicine Doctor and world recognized speaker in neurofeedback and brain regeneration. 

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 05,2019

CeQur Appoints Bradley Paddock Chief Executive Officer

CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably

View Analyst & Ambassador Comments
Go to original news
Jun 05,2019

New Virta Health Results Show Sustained Type 2 Diabetes Reversal at Two Years and Continued Reduction of Insulin

Virta Health, the first company with a treatment to safely and sustainably reverse type 2 diabetes (T2D), today announced the publication of two-year peer-reviewed research from its ongoing clinical trial, now over three years in duration. Published in Frontiers in Endocrinology, the results demonstrate sustained diabetes reversal—reducing HbA1c below the diagnostic threshold for T2D while eliminating diabetes-specific medications—in 54% of two-year completing patients

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 06,2019

Insulet to Showcase its Recently-Launched Omnipod® DASH™ System and Present Seven Scientific Abstracts at the American Diabetes Association's 79th Scientific Sessions

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will showcase its new Omnipod DASH™ Insulin Management System (Omnipod DASH System), during the American Diabetes Association (ADA) 79th Scientific Sessions at the Moscone Center in San Francisco, California, June 7-11, 2019.

CONFERENCES

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 06,2019

Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data

DexCom, Inc. and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 08,2019

Pilot Study Shows that Investigational Interconnected Diabetes Management Solution from Ascensia Significantly Reduced HbA1c in People with Type 2 Diabetes

The study found that the use of Ascensia’s investigational IDMS was associated with a significant decrease in HbA1c levels in people with type 2 diabetes, independent of any changes to diabetes medication, suggesting that the solution could lead to improved self-care and better glycemic control. As the primary endpoint, mean HbA1c significantly decreased by 0.43%, from 8.44% at the start to 8.01% after 12 weeks.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 08,2019

Medtronic Initiates Pivotal Trial for Next-Generation Guardian(TM) Continuous Glucose Monitoring Sensor

Medtronic plc, the global leader in medical technology, today announced that it has initiated the company's pivotal trial for its next-generation Guardian(TM) continuous glucose monitoring (CGM) sensor designed to improve accuracy and overall system performance, reduce sensor calibrations and enhance overall user experience.

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES